Melissa Putman is an Endocrinology/Metabolic physician affiliated with Joslin Diabetes Center. OpenAlex indexes 119 publications with 1,842 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Telephone
617-726-7782Registry record last updated 14 Jun 2012.
Clinical trials
- Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Sponsor: Massachusetts General Hospital
- Bionic Pancreas in CFRD
Sponsor: Jaeb Center for Health Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20255 payments$12,127openpaymentsdata.cms.gov ↗
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20254 payments
- Dexcom, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
64.7%l-Thyroxine26.5%Levothyroxine Sodium100%Part D<11 patientsAntihypoglycemic Agent19.1%Gvoke Hypopen 2-Pack100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
19.1%Insulin Analog19.1%Lantus100%Part D<11 patientsCardiovascular
16.2%Thiazide diuretic16.2%Hydrochlorothiazide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Clinical Studies Investigating Use of the Bionic Pancreas in Pregnancy
Massachusetts General Hospital
FY2026$708,133R01DK140780 - Clinical Studies Investigating Use of the Bionic Pancreas in Pregnancy
Massachusetts General Hospital
FY2025$725,192R01DK140780 - Clinical Studies Investigating Use of the Bionic Pancreas in Pregnancy
Massachusetts General Hospital
FY2024$725,628R01DK140780
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Lloyd Aiello, MD, PhD
Joslin Diabetes Center
Sylvia Rosas, MD
Joslin Diabetes Center
Jason Gaglia, MD
Joslin Diabetes Center
Mary Horlick
Joslin Diabetes Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”